In-House Patent Attorney, Biotechnology

Position
In-House Patent Attorney, Biotechnology


Recruiter
Fellows and Associates


Location
London


Salary
Competitive


Date
28 July 2017


Apply now
Silence Therapeutics is poised at an exciting time in its growth, and is expanding its IP portfolio. As Silence intensifies its efforts in the field of RNAi Therapeutics, and is the only European listed organisation in the field, there is need for additional resource within its IP function.

Silence Therapeutics are able to offer a patent attorney opportunity that is highly varied and will require European travel. You will work very closely with R&D departments and enjoy a collaborative environment where you will develop IP strategies in conjunction with scientific staff.

Key responsibilities include:

Patent drafting and FTO work

UK and European prosecution

Preparing responses to reports from patent examiners

Discussing inventions and processes with scientific staff to ascertain patent application
viability

Researching scientific and/or technical documents, including previously granted patents, to assess
whether an invention is new and innovative

Advising on potential IP infringements

Working with solicitors and barristers to defend or enforce UK patents

Supporting litigation in proceedings at the EPO or in the Intellectual Property Enterprise Court
(IPEC)

Patent valuation

Candidate profile:

Candidates should be either qualified UK and European patent attorneys, or near qualified
(finalist) with the expectation of qualification within the next year to eighteen months.
Attorneys should have an academic and technical background in biotechnology.

About Silence Therapeutics

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural
mechanism of RNA interference, or RNAi, within its cells. Their proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease
causing proteins. Using their enabling delivery systems, they have achieved an additional level of
specificity by delivering therapeutic RNA molecules exclusively to target cells. Silence’s
proprietary RNA chemistries and delivery systems are designed to improve the stability of their
molecules and enhance effective delivery to target cells, providing a powerful modular technology
well suited to tackle life threatening diseases.



The company is located in London and Berlin with a total of around 55 employees. The majority of
the scientific operation and employee base is located in Berlin with corporate headquarters in
London.





Features
The latest features from IPPro The Internet
INTA’s anti-counterfeiting committee services its members worldwide with up-to-date enforcement advice, as Heather McDonald tells Barney Dixon
As EU copyright reform continues, publishers are insisting the press publisher’s right will be good for business and won’t harm consumers. Angela Mills Wade of the European Publishers Council explains
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
ECTA’s copyright committee was formed in response to the modernisation of the EU’s approach to copyright. Chair Dr Christian Freudenberg tells Mark Dugdale what this has meant in practice
ECTA has ramped up its efforts to ensure that IP rights are heard in Brexit negotiations. But this isn’t all the trademark association has been up to in the past year, as Ruta Olmane explains
William Dyer III and Bea Koempel-Thomas of Lee & Hayes examine TC Heartland v Kraft and the arguments put forward in support of each party
As Brexit negotiations begin, it is still unclear where trademarks fit in. But, with two years to get a good deal, the UK government needs to consider all aspects
Rights holders that want to protect their valuable intellectual property have to be willing to change
Alternative dispute resolution mechanisms are not being used to their full potential, according to IPzen’s Julia Cytrynbaum
Country profiles
The latest country profiles from IPPro The Internet
While Indian fair use is not explicit, provisions exist for the fair dealing of copyright. Rohit Singh and Tina Canneth of Abu-Ghazeleh Intellectual Property delve deeper
An interpretation of the current events exception in Radosavljević is creative, say BDK Advokati's Bogdan Ivanišević and Marko Popović
IPPro Patents

Visit our sister site
for all the latest IP patents news and analysis

ippropatents.com
Yu-Li Tsai of Deep & Far examines how damages are calculated in patent infringement litigation
A recent amendment will make costly annulments a thing of the past. Gilberto Sanchez of SPECyF explains
New legislation in Turkey promises a swathe of trademark changes. Dr Cahit Suluk of Cahit Suluk Intellectual Property Law Firm explains
A trademark decision clarified ‘against the public order’ as an absolute ground for refusal. Sár and Partners – Danubia Patent & Law Office reports
Bogdan Ivanišević and Marko Popović of BDK Advokati review the recent squabble about copyright protection for ‘routinely created photos’
Alston & Bird recently expanded with a new office focusing on counselling Chinese companies on US intellectual property law. Yitai Hu explains what patent owners face when working across borders
Interviews
The latest interviews from IPPro The Internet